Medpace Holdings, Inc.

MEDPSEC EDGAR

Services-Commercial Physical & Biological Research(DE)CIK: 1668397

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$1.9B	$1.5B	$1.1B	$925.9M	$861.0M
Selling, General and Administrative Expense	$161.4M	$131.4M	$108.4M	$92.2M	$95.2M
Operating Income (Loss)	$336.8M	$278.7M	$198.6M	$167.0M	$127.3M
Nonoperating Income (Expense)	-$1.1M	$4.2M	$3.2M	$1.5M	-$2.4M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$335.7M	$282.9M	$201.9M	$168.5M	$124.8M
Income Tax Expense (Benefit)	$52.9M	$37.5M	$20.0M	$23.1M	$24.4M
Net Income (Loss) Attributable to Parent	$282.8M	$245.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$2.1B	$1.7B	$1.4B	$1.7B	$1.0B
Assets, Current	$1.0B	$593.8M	$334.0M	$690.9M	$177.7M
Cash and Cash Equivalents, at Carrying Value	$669.4M	$245.4M	$28.3M	$461.3M	$277.8M
Liabilities	$1.3B	$1.1B	$966.1M	$707.0M	$405.9M
Liabilities, Current	$1.1B	$925.1M	$803.5M	$557.2M	$263.1M
Long-term Debt	—	—	—	—	—
Accounts Payable, Current	$32.5M	$31.9M	$33.1M	$25.7M	$26.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$433.4M	$388.1M	$263.3M	$258.7M	$201.9M
Net Cash Provided by (Used in) Investing Activities	-$34.6M	-$38.7M	-$31.4M	-$31.2M	-$19.1M
Net Cash Provided by (Used in) Financing Activities	-$182.6M	-$775.8M	-$44.5M	-$82.3M	-$73.9M
Payments to Acquire Property, Plant, and Equipment	$36.6M	$36.9M	$28.3M	$31.3M	$17.9M
Payments for Repurchase of Common Stock	$144.0M	$847.8M	$62.1M	$98.3M	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)